Article Author:
Mark Marino

Article Editor:
Marco Siccardi

Editors In Chief:
Jasleen Jhajj
Cliff Caudill
Evan Kaufman

Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi

1/25/2019 11:05:54 PM


Pharmaceutics is the overall process of developing a new chemical entity into an approved therapeutic that is safe and effective to treat or prevent a disease. It is a complex process requiring multiple scientific, medical, legal, commercial and regulatory expertise. On average, it typically takes at least ten years for a new drug to complete the process from initial discovery to the retail marketplace, with clinical trials alone taking six to seven years on average. The Tufts Center for the Study of Drug Development announced it had calculated that it costs pharmaceutical companies $2.6 billion to develop a new drug.[1] This figure has been subject to question, as the raw numbers on which they base the analysis have not been made available. The driving factor of this estimate is the cost of failed drug development attempts, with 80% of new compounds discontinued during their development. The steps involved in bringing a new chemical entity to the market as a drug involve the stages of discovery, chemical optimization and production, preclinical testing, pharmacology and toxicology testing, early clinical trials establishing proof of concept, registration or pivotal clinical trials showing safety and efficacy in the target patient population and finally regulatory approval.

Issues of Concern

The discovery phase of the pharmaceutics process involves establishing a receptor, enzyme, protein, RNA, DNA or protein that modulates a biochemical process, as a potential contributor to the pathophysiology of a disease process. They often base this on literature reviews of basic science investigating disease mechanisms. For example, the immune regulating receptor PD-1 and its ligand PD-L1 were implicated in reducing the immune system's response to cancer.[2]The next stage in the development of PD-1 therapy was then to develop monoclonal antibodies targeted against an area of those proteins that would assure good binding and inhibition of effect. They established in-vitro and in-vivo models to show antibody binding and reactivation of the immune system towards a cancer model. For traditional small molecules, a similar process occurs but usually with a screening of activity against a target (typically a receptor or enzyme) against a library of compounds. Enzyme inhibitors such as kinase inhibitors against  BCR-ABL1 in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia with the Philadelphia chromosome are just one example.[3]

The chemical optimization and production phases focus on improving the drug and manufacturing characteristics of the drugs found in the discovery phase. With antibodies, for example, this would include the selection of the proper sub-type of antibody to prolong its half-life in the body and to enhance or suppress complement fixation or antibody-dependent cell cytotoxicity (ADCC).[4]This would also be the step to determine what type of cell and bio-incubator should be used to produce the product. Chemical optimization for small molecules involves changing the chemical structure such that it enhances the therapeutic effect while minimizing the interaction of the drug with CYP450s and transporter protein and HERG or sodium channels involved in cardiac conduction. At this stage is when screening for interactions across a large panel of receptors and transporters takes place, and when patents get submitted. An important issue regards the use of the excipients, often considered as inert, but these have caused problems both in the pediatric and adult population.

Preclinical testing, pharmacology, and toxicology testing involve using models of the disease tested. Often these animal models harbor close approximations of the human disease, such as human tumor implants in immune-incompetent mice (xenograft tumor models) or are a relatively poor approximation of human pathologies, such as the forced swimming test. Standard pharmacology models involving testing for cardiovascular, CNS and renal effects are performed in in-vitro and in-vivo models such as I(Kr) potassium channel antagonism and prolongation of the QT interval is assessed in telemetered dogs. These are often not required for targeted drugs such as antibodies. Toxicology testing involves standard protocols with doses and duration’s that extend beyond the expected human dosing (in animal lifetimes). These are often used to determine the first dose used in human trials and determine any particular toxicity concerns that will require monitoring in the early clinical trials. 

Clinical Significance

Initiation of early clinical trials after establishing proof of a concept commence after an Investigational New Drug Application (IND) has been reviewed and approved by the FDA. Similar procedures are used in the EMA, Japan, and other countries; although some nations limit the testing of new drugs for the first time. The initial studies in humans can be in actual patients if the toxicity of the drug or its target would not be appropriate to use in volunteers. Increasing doses of drug are used to establish the drugs' safety and determine the drugs' pharmacokinetics (the duration and extent of the drug in the body) as well as measure the drugs' effect on biomarkers (serum or tissue enzymes, histology, or any other measure of drug effect such as glucose in diabetes). This data will be used to select doses to be brought into a proof of concept or phase 2 studies in a select patient population. Clinical trials like the TeGenero disaster, are fortunately the exception, and not the rule. In this study, the first volunteers received a dose that was 500 times smaller than the safe dose as established in animal studies. However, all six human volunteers faced life-threatening conditions, involving multiorgan failure, which required transfer to the intensive care unit. As a result, the implementation of new precautions and toxicity calculations became standard since that 2006 incident.[5]

Registration or pivotal clinical trials demonstrate safety and efficacy in the target patient population. These trials may encompass thousands of patients, or only a small number (as in ultra-rare diseases). The outcomes vary between pathologies and range from overall survival (in oncology indications), to a reduction in the incidence of asthma exacerbations requiring hospitalizations, to effects on a biomarker like HbA1C in patients with diabetes. Patient selection is crucial in order to match the drug effects with the target patient population, but the data from the studies must also be able to be extrapolated to the broader patient population. Endpoint selection is crucial in that it must reflect a meaningful alteration in patient outcomes but also be statistically achievable with the study design. These studies often take several years to complete and analyze.

Once the entire drug development package is complete with reports from discovery, preclinical, chemistry, manufacturing, and clinical a regulatory submission takes place that integrates all of this data in a standard format. The submission can be many terabytes of data. Regulatory approval can take around a year with often an outside review by experts (FDA Advisory Board) and a public hearing. If all goes well the drug receives marketing approval and becomes available for patients.

Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Pharmaceutics - Questions

Take a quiz of the questions on this article.

Take Quiz
Incompatibility is termed when two or more ingredients are mixed and an undesirable change occurs. Which types of properties of the drug are involved?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up
What is the definition of stability of a pharmaceutical product?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up
Drug delivery systems, such as tablets, pills, creams, liquids have advantages and disadvantages. Which of the following is not an advantage for patients?

Click Your Answer Below

Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.

Sign Up

Pharmaceutics - References


Avorn J, The $2.6 billion pill--methodologic and policy considerations. The New England journal of medicine. 2015 May 14     [PubMed]
Yang Y, Cancer immunotherapy: harnessing the immune system to battle cancer. The Journal of clinical investigation. 2015 Sep     [PubMed]
Gross S,Rahal R,Stransky N,Lengauer C,Hoeflich KP, Targeting cancer with kinase inhibitors. The Journal of clinical investigation. 2015 May     [PubMed]
Rogers LM,Veeramani S,Weiner GJ, Complement in monoclonal antibody therapy of cancer. Immunologic research. 2014 Aug     [PubMed]
Attarwala H, TGN1412: From Discovery to Disaster. Journal of young pharmacists : JYP. 2010 Jul     [PubMed]


The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Optometry-Basic Science. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Optometry-Basic Science, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Optometry-Basic Science, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Optometry-Basic Science. When it is time for the Optometry-Basic Science board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Optometry-Basic Science.